Yescarta
is a Private company. Yescarta has 1 followers on Owler. Yescarta has an estimated revenue of <$1M and an estimate of less <10 employees.Yescarta
is a Private company. Yescarta has 1 followers on Owler. Yescarta has an estimated revenue of <$1M and an estimate of less <10 employees.
CEO
Add
Est. Annual Revenue
<$1M
Est. Employees
<10
News
Dec 10, 2024
centralcharts
Press Release: Yescarta : Kite's Yescarta Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
Jun 18, 2024
Medthority
Yescarta : New clinical research and real-world evidence for Yescarta (axicabtagene ciloleucel (Axi-Cel)) demonstrate benefit From earlier lines of treatment
Jun 03, 2024
BioSpace
Yescarta : Encouraging New Data Presented on Kite's Yescarta for Relapsed/Refractory Central Nervous System Lymphoma
Dec 24, 2023
Medthority
Yescarta : FDA approves label update for Yescarta CAR T-Cell therapy to include overall survival data for patients with relapsed or refractory large B-cell lymphoma .- Kite/Gilead
Nov 17, 2023
Yicai Global
Yescarta : China's Medical Insurance Will Not Cover Fosun Kite's Costly CAR-T Cell Therapy
Sep 19, 2023
Medthority
Yescarta : Yescarta demonstrates high response rate and durable remission in ALYCANTE study as initial treatment for transplant ineligible patients with r/r Large B-cell lymphoma